CN110392686A - 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法 - Google Patents

1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法 Download PDF

Info

Publication number
CN110392686A
CN110392686A CN201780087768.9A CN201780087768A CN110392686A CN 110392686 A CN110392686 A CN 110392686A CN 201780087768 A CN201780087768 A CN 201780087768A CN 110392686 A CN110392686 A CN 110392686A
Authority
CN
China
Prior art keywords
alkyl
cells
compound
halogen
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780087768.9A
Other languages
English (en)
Chinese (zh)
Inventor
C.卢斯
B.泰特
R.曼钱达
W.麦克莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korro Bio Inc
Original Assignee
Frequency Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frequency Therapeutics Inc filed Critical Frequency Therapeutics Inc
Publication of CN110392686A publication Critical patent/CN110392686A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780087768.9A 2016-12-30 2017-12-21 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法 Pending CN110392686A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662441060P 2016-12-30 2016-12-30
US62/441060 2016-12-30
US201762484282P 2017-04-11 2017-04-11
US62/484282 2017-04-11
PCT/US2017/067885 WO2018125746A1 (en) 2016-12-30 2017-12-21 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells

Publications (1)

Publication Number Publication Date
CN110392686A true CN110392686A (zh) 2019-10-29

Family

ID=60972503

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780087768.9A Pending CN110392686A (zh) 2016-12-30 2017-12-21 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法

Country Status (12)

Country Link
US (2) US11066419B2 (enExample)
EP (1) EP3562827A1 (enExample)
JP (1) JP7109446B2 (enExample)
KR (1) KR20190104359A (enExample)
CN (1) CN110392686A (enExample)
AU (1) AU2017386417B2 (enExample)
BR (1) BR112019013388A2 (enExample)
CA (1) CA3048220A1 (enExample)
IL (1) IL267601A (enExample)
MX (1) MX390321B (enExample)
SG (1) SG10201910821XA (enExample)
WO (1) WO2018125746A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111205231A (zh) * 2020-02-24 2020-05-29 浙江大学 作为ankrd22抑制剂的先导化合物及其应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
MX390321B (es) 2016-12-30 2025-03-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
EP3837350A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating pi3k
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
MX2021003773A (es) 2018-10-02 2021-07-16 Frequency Therapeutics Inc Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
US20220160664A1 (en) 2019-02-08 2022-05-26 Frequency Therapeutics, Inc. Taz activators and wnt agonists for treating ear disorders
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
WO2020163814A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by inhibiting epigenetic targets
BR112021020141A2 (pt) 2019-04-08 2021-12-21 Frequency Therapeutics Inc Combinação de chir99021 e ácido valpróico para tratamento de perda auditiva
US12371463B2 (en) 2021-04-20 2025-07-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and compositions for treatment of antibiotic-resistant bacterial infections
EP4337321A4 (en) * 2021-05-12 2025-03-19 University of Pittsburgh - of the Commonwealth System of Higher Education MANIPULATED ANTIMICROBIAL PEPTIDES AND THEIR USE

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721245A (en) * 1989-02-23 1998-02-24 Hoffmann-La Roche Inc. 4- 3-indolyl!-1H-pyrrolone
US20030229026A1 (en) * 1999-12-16 2003-12-11 Al-Awar Rima Salim Agents and methods for the treatment of proliferative diseases
WO2004058720A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of 1,3,5-substitute indazole derivatives as compounds for targetting compounds capable of binding to the g-protein coupled receptor
CN1639165A (zh) * 2002-03-05 2005-07-13 伊莱利利公司 作为激酶抑制剂的嘌呤衍生物
CN101133055A (zh) * 2005-02-09 2008-02-27 艾科优公司 用于治疗癌症的meleimide衍生物、药物组合物以及方法
CN102276615A (zh) * 2011-08-26 2011-12-14 四川大学 一种制备甲酰阿地咪的方法
WO2013126805A2 (en) * 2012-02-24 2013-08-29 Fate Therapeutics, Inc. Small molecule compounds to treat hearing loss
WO2014210159A1 (en) * 2013-06-26 2014-12-31 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
CN104583213A (zh) * 2012-06-18 2015-04-29 达特神经科学(开曼)有限公司 取代的吡啶唑并嘧啶-5-(6h)-酮化合物
CN110869492A (zh) * 2017-04-11 2020-03-06 频率治疗公司 用于毛囊干细胞增殖的方法

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5731144A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US6124449A (en) 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5561163A (en) 1990-08-31 1996-10-01 Deprenyl Animal Health, Inc. Treating hearing loss with deprenyl
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5837681A (en) 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6045528A (en) 1997-06-13 2000-04-04 Intraear, Inc. Inner ear fluid transfer and diagnostic system
US6639051B2 (en) 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
US6806358B1 (en) 1997-12-16 2004-10-19 University Of California San Diego Peptide inhibitor of TGF-β growth factors
US6177434B1 (en) 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
WO1999043636A2 (en) 1998-02-27 1999-09-02 The United States Of America As Represented By Thesecretary Of The Department Of Health And Human Services Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
WO2000059939A1 (en) 1999-04-05 2000-10-12 Adherex Technologies Inc. COMPOUNDS AND METHODS FOR STIMULATING β-CATENIN MEDIATED GENE EXPRESSION AND DIFFERENTIATION
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
JP2001275095A (ja) 2000-03-27 2001-10-05 Sony Corp 通信方法、通信サービス装置、通信端末装置および通信システム
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US20050070578A1 (en) 2000-03-30 2005-03-31 Baxter Anthony David Small organic molecule regulators of cell proliferation
WO2001074344A2 (en) 2000-03-30 2001-10-11 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683108B1 (en) 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
AU2001253012B2 (en) 2000-03-31 2006-02-23 The General Hospital Corporation Methods of modulating hair growth
CA2408747C (en) 2000-05-11 2011-04-05 Consejo Superior Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase gsk-3
US6509318B1 (en) 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
MXPA03004832A (es) 2000-12-01 2004-05-04 Guilford Pharm Inc Compuestos y sus usos.
KR20040016828A (ko) 2000-12-08 2004-02-25 오르토-맥네일 파마슈티칼, 인코퍼레이티드 키나제 저해제로서 인다졸릴-치환된 피롤린 화합물
US20050227936A1 (en) 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
HRP20030961B1 (en) 2001-05-24 2012-01-31 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
US20030028905A1 (en) 2001-07-31 2003-02-06 Petra Knaus Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
MXPA04004178A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US20040006030A1 (en) 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of TGF-beta 2 expression
AU2003224335A1 (en) 2002-05-15 2003-12-02 Smithkline Beecham Corporation Benzoxazine and benzoxazinone substituted triazoles
WO2003097615A1 (en) 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
US7190468B2 (en) 2002-07-17 2007-03-13 Hewlett-Packard Development Company, L.P. Background document rendering system and method
AU2003260345A1 (en) 2002-07-31 2004-02-23 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
SI1532145T1 (sl) 2002-08-02 2007-02-28 Vertex Pharma Pirazolni sestavki, koristni kot inhibitorji GSK-3
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
EP1543001B1 (en) 2002-09-17 2007-08-15 Eli Lilly And Company Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer
OA12925A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors.
OA12927A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Novel triazole and oxazole compounds as transforming growth factor (TGF) inhibitors.
US7273864B2 (en) 2002-10-15 2007-09-25 The Scripps Research Institute Compositions and methods for inducing osteogenesis
US20040138188A1 (en) 2002-11-22 2004-07-15 Higgins Linda S. Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors
JP2006516603A (ja) 2003-01-27 2006-07-06 ファイザー・プロダクツ・インク イソチアゾール誘導体
US7189733B2 (en) 2003-03-12 2007-03-13 Millennium Pharmaceuticals, Inc. Compositions and methods for inhibiting TGF-β
CA2520465A1 (en) 2003-03-28 2004-10-14 Scios Inc. Bi-cyclic pyrimidine inhibitors of tgf.beta.
EP1633718B1 (en) 2003-06-17 2012-06-06 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-s
GB0316756D0 (en) 2003-07-17 2003-08-20 Bp Chem Int Ltd Process
WO2005019422A2 (en) 2003-08-13 2005-03-03 The Board Of Trustees Of The University Of Illinois Silencing of tgf-beta receptor type ii expression by sirna
US7387614B2 (en) 2003-08-26 2008-06-17 University Of Maryland, Baltimore Drug delivery to the inner ear and methods of using same
WO2005039570A1 (ja) 2003-10-28 2005-05-06 Riken ＴＧＦ－β情報伝達経路阻害剤
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
GB0327908D0 (en) 2003-12-02 2004-01-07 Neuropharma Sa GSK-3 inhibitors isolated from marine organisms
BRPI0417213A (pt) 2003-12-24 2007-02-06 Scios Inc tratamento de gliomas malìgnos com inibidores de tgf-beta
EP1723146A1 (en) 2004-03-01 2006-11-22 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
US8870826B2 (en) 2004-05-24 2014-10-28 Auris Medical Llc Combined otic aspirator and medication dispenser
GB0418328D0 (en) 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
JP2007176795A (ja) 2004-08-18 2007-07-12 Univ Nihon ＴＧＦ−β遺伝子発現抑制剤
WO2006034207A2 (en) 2004-09-17 2006-03-30 Vanderbilt University Use of gsk3 inhibitors in combination with radiation therapies
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
GB0505970D0 (en) 2005-03-23 2005-04-27 Univ Edinburgh Culture medium containing kinase inhibitor, and uses thereof
CN101189234B (zh) 2005-03-25 2011-08-17 泰博特克药品有限公司 Hcv的杂二环抑制剂
ES2931949T3 (es) 2005-03-29 2023-01-05 Univ Pennsylvania Minoxidilo para generar nuevos folículos pilosos y tratar la calvicie
ES2387402T3 (es) 2005-03-31 2012-09-21 Stemnion, Inc. Composiciones celulares derivadas del amnios, procedimientos de fabricación y usos de las mismas
BRPI0612888B8 (pt) 2005-06-30 2022-12-27 Janssen Pharmaceutica Nv anilino-piridinotriazinas cíclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica
RS53999B1 (sr) 2005-07-22 2015-10-30 Eli Lilly And Company Piridin hinolin supstituisani pirolo [1,2-b] pirazol monohidrat kao tgf-beta inhibitor
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
JP5112322B2 (ja) 2005-10-24 2013-01-09 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ 免疫応答調節剤の製造におけるＴＧＦ−β１インヒビターペプチドの使用
US7951845B2 (en) 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
ITMI20060181A1 (it) 2006-02-03 2007-08-04 Univ Padova Modulatori del tgf-b e loro uso
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
WO2007109097A2 (en) 2006-03-16 2007-09-27 Alnylam Pharmaceuticals, Inc. RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
ES2641528T3 (es) 2006-06-27 2017-11-10 Shiseido Company, Limited Masa celular capaz de servir como estructura de tipo órgano primitivo compuesta por una diversidad de tipos de células de origen somático
TWM303325U (en) 2006-07-13 2006-12-21 Everlight Electronics Co Ltd Light emitting diode package
MX2009001913A (es) 2006-08-23 2009-03-06 Pfizer Prod Inc Compuestos de pirimidona como inhibidores de gsk-3.
JP5138253B2 (ja) 2006-09-05 2013-02-06 東京エレクトロン株式会社 アニール装置
US20090214474A1 (en) 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
WO2008057497A2 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
US20080194637A1 (en) 2006-11-02 2008-08-14 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2008057468A1 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
EP2146724A2 (en) 2007-03-16 2010-01-27 The Regent of the University of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
DE102007021348A1 (de) 2007-05-06 2008-11-20 Universitätsklinikum Hamburg-Eppendorf (UKE) Verfahren zur Simulation der Haptik einer Interaktion eines geführten Gegenstandes mit einem virtuellen dreidimensionalen Objekt
CA2690799C (en) 2007-06-22 2015-06-16 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
DE102007032977A1 (de) 2007-07-16 2009-01-22 Universität Tübingen Neue Cyclische Amide, Verfahren zu deren Herstellung und ihre Verwendung
WO2009017453A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
WO2009017455A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
US20110190280A1 (en) 2007-08-29 2011-08-04 George Adjabeng Thiazole And Oxazole Kinase Inhibitors
US8377886B2 (en) 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
CN101951915A (zh) 2007-12-03 2011-01-19 加利福尼亚大学董事会 用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇
EP2242476A2 (en) 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
JP5951254B2 (ja) 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
BRPI0910850B1 (pt) 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
WO2009142719A2 (en) 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
US20120059021A1 (en) 2008-11-11 2012-03-08 University Of Washington Compositions and methods for treating cancer and methods for predicting a response to such treatments
US10143711B2 (en) 2008-11-24 2018-12-04 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
EP2376626A4 (en) 2008-12-13 2012-10-17 Dna Microarray MICRO-ENVIRONMENTAL NICHE ASSAY FOR SCREENING OF INDUCED PLURIPOTENT STEM CELLS (CIPS)
US20130039998A1 (en) 2008-12-24 2013-02-14 University Of Washington Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder
GB201111244D0 (en) 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
KR101748891B1 (ko) 2009-03-11 2017-06-19 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-3 억제제로서의 7-시클로알킬아미노퀴놀론
US20120095445A1 (en) 2009-06-17 2012-04-19 Aderans Research Institute, Inc. Methods and compositions for increasing trichogenic potency of dermal cells
WO2011019957A1 (en) 2009-08-12 2011-02-17 University Of Southern California Method for formation of induced pluripotent stem cells
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
DK2494039T3 (da) 2009-10-31 2019-08-19 Genesis Tech Limited Fremgangsmåder til reprogrammering af celler og anvendelser deraf
US20110135756A1 (en) 2009-12-08 2011-06-09 University Of Washington Compositions and methods for protecting sensory hair cells
BR112012015967B1 (pt) 2009-12-28 2019-08-27 Audiocure Pharma Gmbh uso de compostos de fórmula geral (i) e composição farmacêutica
US8198285B2 (en) 2010-01-19 2012-06-12 Astrazeneca Ab Pyrazine derivatives
WO2011109711A1 (en) 2010-03-05 2011-09-09 Duke University Glucocorticoid drugs as smoothened agonists
WO2011116930A1 (en) 2010-03-22 2011-09-29 Cellartis Ab Directed differentiation and maturation of pluripotent cells into hepatocyte like cells by modulation of wnt-signalling pathway
CN109593814A (zh) 2010-05-12 2019-04-09 哥伦比亚大学纽约管理委员会 筛选分析、鉴别药剂的方法及药物组合物
ES2879314T3 (es) 2010-08-18 2021-11-22 Biosplice Therapeutics Inc Dicetonas e hidroxicetonas como activadores de la vía de señalización de catenina
WO2012024584A2 (en) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024581A2 (en) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024583A2 (en) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
JP5875007B2 (ja) 2010-11-02 2016-03-02 国立大学法人 熊本大学 腸細胞の製造方法
FR2967498B1 (fr) 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
WO2012103012A1 (en) 2011-01-24 2012-08-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for generating inner ear cells in vitro
WO2012115575A1 (en) 2011-02-21 2012-08-30 Biomatcell Ab Derivatives for inducing osteogenic differentiation
AU2012308570B2 (en) 2011-09-14 2016-11-10 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors
WO2013051722A1 (ja) 2011-10-06 2013-04-11 学校法人 慶應義塾 角膜内皮細胞の製造方法
WO2013124413A1 (en) 2012-02-24 2013-08-29 Noscira, S.A. Thiadiazolidinediones as gsk-3 inhibitors
US9457009B2 (en) 2012-05-31 2016-10-04 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for preventing and treating auditory dysfunctions
TW201406758A (zh) 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
GB201212960D0 (en) 2012-07-20 2012-09-05 Common Services Agency Erythroid production
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
TW201417817A (zh) 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
HUE043853T2 (hu) 2012-10-12 2019-09-30 Broad Inst Inc GSK3 inhibitorok és eljárások azok alkalmazására
EP2925363A4 (en) 2012-11-29 2016-11-09 Strasspharma Llc METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY
EP2925859B1 (en) 2012-11-29 2018-05-02 Takara Bio Europe AB Maturation of hepatocyte-like cells derived from human pluripotent stem cells
US20140248696A1 (en) 2013-03-01 2014-09-04 Wisconsin Alumni Research Foundation Methods of maintaining, expanding, and diffrentiating neuronal subtype specific progenitors
US20160115167A1 (en) 2013-03-04 2016-04-28 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
DK2970890T3 (da) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
US9683009B2 (en) 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
US10603295B2 (en) 2014-04-28 2020-03-31 Massachusetts Eye And Ear Infirmary Sensorineural hair cell differentiation
WO2015175783A1 (en) 2014-05-15 2015-11-19 International Stem Cell Corporation Chemical differentiation of pluripotentstem cells into retinal epithelial cells
US9795550B2 (en) 2014-08-20 2017-10-24 Samumed, Llc Gamma-diketones for treatment and prevention of aging skin and wrinkles
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
JP2017536411A (ja) 2014-10-01 2017-12-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US9913848B2 (en) 2016-03-02 2018-03-13 Frequency Therapeutics, Inc. Methods for controlled proliferation of stem cells / generating inner ear hair cells using 1,2,3,4-tetrahydro-[1,4]diazepino[6,7, 1-hi]indolyl based compounds
US10016507B2 (en) 2016-03-02 2018-07-10 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III
MX390321B (es) 2016-12-30 2025-03-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
US10383881B2 (en) 2016-12-30 2019-08-20 Frequency Therapeutics, Inc. 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
US20200316089A1 (en) 2017-12-21 2020-10-08 Frequency Therapeutics, Inc. 1,2-dihydro-3h-pyrazol-3-one compounds and methods of using same
WO2019126686A1 (en) 2017-12-21 2019-06-27 Frequency Therapeutics, Inc. 1,2-dihydro-3h-pyrazol-3-one compounds and methods of using same

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721245A (en) * 1989-02-23 1998-02-24 Hoffmann-La Roche Inc. 4- 3-indolyl!-1H-pyrrolone
US20030229026A1 (en) * 1999-12-16 2003-12-11 Al-Awar Rima Salim Agents and methods for the treatment of proliferative diseases
CN1639165A (zh) * 2002-03-05 2005-07-13 伊莱利利公司 作为激酶抑制剂的嘌呤衍生物
WO2004058720A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of 1,3,5-substitute indazole derivatives as compounds for targetting compounds capable of binding to the g-protein coupled receptor
CN101133055A (zh) * 2005-02-09 2008-02-27 艾科优公司 用于治疗癌症的meleimide衍生物、药物组合物以及方法
CN102276615A (zh) * 2011-08-26 2011-12-14 四川大学 一种制备甲酰阿地咪的方法
WO2013126805A2 (en) * 2012-02-24 2013-08-29 Fate Therapeutics, Inc. Small molecule compounds to treat hearing loss
CN104583213A (zh) * 2012-06-18 2015-04-29 达特神经科学(开曼)有限公司 取代的吡啶唑并嘧啶-5-(6h)-酮化合物
WO2014210159A1 (en) * 2013-06-26 2014-12-31 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
CN110869492A (zh) * 2017-04-11 2020-03-06 频率治疗公司 用于毛囊干细胞增殖的方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COLUMBUS,OHIO,US REGISTRY[ONLINE]: "《STN检索报告》", 7 January 2015 *
HENDRA GUNOSEWOYO等，: ""Characterization of Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as Stimulators of Steroidogenesis"", 《J. MED. CHEM.》 *
LILY L. REMSING RIX等，: ""GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells"", 《ACS CHEM. BIOL.》 *
PRASHANT JOSHI等，: ""(Z)-2-(3-Chlorobenzylidene)-3,4-dihydro-N-(2-methoxyethyl)-3-oxo-2H-benzo[b][1,4]oxazine-6-carboxamide as GSK-3β inhibitor: Identification by virtual screening and its validation in enzyme-and cell-based assay"及其Supporting Information", 《CHEM BIOL DRUG DES.》 *
劳艳萍等，: ""糖原合成激酶抑制剂在胚胎干细胞自我更新中的作用"", 《中国畜牧兽医》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111205231A (zh) * 2020-02-24 2020-05-29 浙江大学 作为ankrd22抑制剂的先导化合物及其应用

Also Published As

Publication number Publication date
BR112019013388A2 (pt) 2020-03-03
MX390321B (es) 2025-03-20
JP2020503340A (ja) 2020-01-30
CA3048220A1 (en) 2018-07-05
EP3562827A1 (en) 2019-11-06
US20210300948A1 (en) 2021-09-30
AU2017386417B2 (en) 2022-07-14
US11066419B2 (en) 2021-07-20
KR20190104359A (ko) 2019-09-09
AU2017386417A1 (en) 2019-07-11
SG10201910821XA (en) 2020-01-30
WO2018125746A1 (en) 2018-07-05
JP7109446B2 (ja) 2022-07-29
US20190352313A1 (en) 2019-11-21
MX2019007890A (es) 2020-01-20
IL267601A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
JP7109446B2 (ja) 幹細胞／前駆支持細胞の自己複製を誘導するための１ｈ－ピロール－２，５－ジオン化合物およびその使用方法
US10383881B2 (en) 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
US20190093079A1 (en) Methods for controlled proliferation of stem cells / generating inner ear hair cells using gsk-3-alpha inhibitors
AU2023201216A1 (en) Methods for controlled proliferation of vestibular stem cells / generating inner ear hair cells using wnt and tgf-beta inhibition
US20200113913A1 (en) Methods for hair follicle stem cell proliferation
US20200121681A1 (en) Methods for hair follicle stem cell proliferation
US20230058189A1 (en) Quinolin-4-one and 4(1h)-cinnolinone compounds and methods of using same
US10220041B2 (en) Methods for controlled proliferation of stem cells / generating inner ear hair cells using 3-(pyridin-2-yl)-1H-indol-2-ol based compounds
US9913848B2 (en) Methods for controlled proliferation of stem cells / generating inner ear hair cells using 1,2,3,4-tetrahydro-[1,4]diazepino[6,7, 1-hi]indolyl based compounds
EP3837351A1 (en) Compositions and methods for generating hair cells by downregulating foxo
WO2019126686A1 (en) 1,2-dihydro-3h-pyrazol-3-one compounds and methods of using same
US9913835B2 (en) Methods for controlled proliferation of stem cells / generating inner ear hair cells using N-(alkylcarbamoyl)-1H-pyrazol-4-yl)-nicotinamide based compounds
US20200316089A1 (en) 1,2-dihydro-3h-pyrazol-3-one compounds and methods of using same
US20210093635A1 (en) Methods for controlled proliferation of stem cells / generating inner ear hair cells using 2-pyrimidinylaminoethylamino-2-pyridyl based compounds
KR101552047B1 (ko) 약 유도 시스템을 이용해 체세포를 도파민 신경세포로 직접교차분화 시키는 방법
KR101552048B1 (ko) 약 유도 시스템을 이용해 혈액세포를 도파민 신경세포로 직접교차분화 시키는 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191029

WD01 Invention patent application deemed withdrawn after publication